Induction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma

  1. Get@NRC: Induction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma (Opens in a new window)
DOIResolve DOI:
AuthorSearch for:
Journal titleImmunopharmacology and Immunotoxicology
Pages465469; # of pages: 5
SubjectCD40 antigen; CD86 antigen; interleukin 6; lipopolysaccharide; STAT3 protein; animal cell; animal tissue; article; bone marrow; cancer cell culture; cancer immunotherapy; cell lineage; cell maturation; colon carcinoma; dendritic cell; down regulation; flow cytometry; mouse; nonhuman; priority journal; protein phosphorylation; Animals; Antigens, CD40; Antigens, CD86; Cell Line, Tumor; Colonic Neoplasms; Dendritic Cells; Immune Tolerance; Immunotherapy; Interleukin-6; Mice; Mice, Inbred BALB C; Neoplasm Proteins; NIH 3T3 Cells; Phosphorylation; STAT3 Transcription Factor; Murinae
AbstractOne scenario by which tumors escape immune recognition is the constitutive activation of signal transducer and activator of transcription 3 (STAT3). This transcription factor mediates the production of tumor-derived factors that negatively influence target immune cells, such as dendritic cells, and polarize them toward immune-tolerance also through the induction of STAT3 activation. In the current study, the effect of p-STAT3-positive murine colon carcinoma cell line (CT26) on bone marrow-derived DCs was examined. The results showed a remarkable increase in p-STAT3 in dendritic cells (DCs) only after CT26-CM incubation. The induction of p-STAT3 in CT26-CM exposed DCs was attributed at least in part to the high levels of interleukin-6 secreted by CT26 in culture. This was also accompanied by a significant reduction in the response to the immunostimulatory adjuvant lipopolysaccharide by lowering the expression of co-stimulatory molecules CD86 and CD40. Taken together, the results suggest an inhibitory effect of CT26 colon carcinoma on DC maturation through induction of STAT3 phosphorylation. Therefore, tumor-induced p-STAT3 in DCs can be seen as a promising target for colon cancer immunotherapy. © 2012 Informa Healthcare USA, Inc.
Publication date
AffiliationNational Research Council Canada (NRC-CNRC); National Institute for Nanotechnology (NINT-INNT)
Peer reviewedYes
NPARC number21269551
Export citationExport as RIS
Report a correctionReport a correction
Record identifiere2ec11df-1df0-4a6f-9c85-09ae2eecd95f
Record created2013-12-12
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)
Date modified: